Vicarious Surgical, Inc. Class A (RBOT)

The share price experienced a significant decline of 82.47% between January 7, 2025, and January 6, 2026. In Q3 2025 earnings were reported on November 12, 2025, where the company reported an EPS of -$1.91, beating analysts' consensus estimates, following this announcement, RBOT shares declined by 9.9%. Q2 2025 saw a narrower loss of $2.23 per share, beating estimates, with operating expenses falling by 24%. In December 2025, Vicarious Surgical announced a reduction in its full-year 2025 cash burn outlook to approximately $45 million, an improvement from previous guidance and also provided full-year 2026 cash burn guidance of approximately $35 million. Concerns about the company's cash position have been noted, with analysts highlighting that the company's cash reserves in March 2025 provided a runway of approximately 9 months given its cash burn rate. In December 2025, Vicarious Surgical announced a strategic software execution partnership to streamline operations and increase development predictability and successfully completed an in-vivo porcine lab in December 2025, a significant step towards its system design freeze targeted for the end of 2026. In August 2025, Vicarious Surgical delayed the initiation of first-in-human clinical trials for its surgical robot, stating a need for more time to ensure the system is design ready. On April 10, 2025, the company received a notice from the NYSE indicating non-compliance with continued listing standards due to its average market capitalization and stockholders' equity falling below $50 million.

There is insufficient data available to reliably determine the demand seasonality for Vicarious Surgical, Inc.'s products and services. The company is currently in a pre-commercialization phase, generating negligible product revenue, as it focuses on clinical development and regulatory approval, therefore, typical demand seasonality patterns for commercialized products do not yet apply.

Vicarious Surgical, Inc. is a medical robotics company in the Healthcare sector, specifically in the Medical Devices and Surgical Devices industry. The company is developing the Vicarious Surgical System, a single-port surgical robot designed to virtually transport surgeons inside the patient's body to perform minimally invasive procedures. The system aims to enhance visualization, precision, and control with human-like robotic arms and immersive 3D visualization, utilizing a single incision as small as 1.5 cm. The technology has received FDA Breakthrough Device Designation. The company's business model is expected to center on sales of capital equipment, recurring revenue from disposable instruments and accessories, and service contracts once commercialized.

Vicarious Surgical, Inc. primarily develops and sells its single-port surgical robot in the United States and is headquartered in Waltham, Massachusetts.

Vicarious Surgical's brand reputation has been shaped by both positive technological advancements and financial challenges. The company benefits from the positive perception associated with its FDA Breakthrough Device Designation for its surgical robot and the successful completion of an in-vivo porcine lab in December 2025. However, the company's reputation has also faced scrutiny due to delays in clinical trial timelines, financial concerns, and workforce reductions.

Vicarious Surgical Inc. has 52 institutional owners and shareholders holding a total of 1,682,873 shares. Major institutional owners include Vk Services, Llc, DDD Partners, LLC, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Aspex Management (HK) Ltd, Comprehensive Financial Management LLC, VEXMX - Vanguard Extended Market Index Fund Investor Shares, MY.Alpha Management HK Advisors Ltd, Geode Capital Management, Llc, Connective Capital Management, LLC, BlackRock, Inc., and AnglePoint Asset Management, Ltd. Major individual and insider owners include Gates Frontier LLC, Dror Berman, Innovation Endeavors III LP, Khosla Ventures Seed C LP, Khosla Ventures V LP, Chelvey International Ltd, Philip Liang, David Chu, and June Morris. Insiders have collectively bought $7.47M worth of shares and sold $1.20M across 100 transactions over the last year, with a strongly positive Insider Power Score.